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Abstract
Background
Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Ital-
ian market. Very limited post-marketing data exist on the comparative effectiveness of biosi-
milar and originator ESAs.
Aim
This population-based study was aimed to compare the effects of biosimilars, reference
product and other ESAs still covered by patent on hemoglobinemia in chronic kidney dis-
ease (CKD) and cancer patients in a Local Health Unit (LHU) from Northern Italy.
Methods
A retrospective cohort study was conducted during the years 2009–2014 using data from
Treviso LHU administrative database. Incident ESA users (no ESA dispensing within 6
months prior to treatment start, i.e. index date (ID)) with at least one hemoglobin measure-
ment within one month prior to ID (baseline Hb value) and another measurement between
2nd and 3rd month after ID (follow-up Hb value) were identified. The strength of the con-
sumption (as total number of defined daily dose (DDD) dispensed during the follow-up
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divided by days of follow-up) and the difference between follow-up and baseline Hb values
[delta Hb (ΔHb)] were evaluated. Based on Hb changes, ESA users were classified as non-
responders (ΔHb0 g/dl), responders (0<ΔHb2 g/dl), and highly responders (ΔHb>2 g/
dl). A multivariate ordinal logistic regression model to identify predictors for responsiveness
to treatment was performed. All analyses were stratified by indication for use and type of
dispensed ESA at ID.
Results
Overall, 1,003 incident ESA users (reference product: 252, 25.1%; other ESAs covered by
patent: 303, 30.2%; biosimilars: 448, 44.7%) with CKD or cancer were eligible for the study.
No statistically significant difference in the amount of dose dispensed during the follow-up
among biosimilars, reference product and other ESAs covered by patent was found in both
CKD and cancer. After three months from treatment start, all ESAs increased Hb values
on average by 2g/dl. No differences in ΔHb as well as in frequency of non-responders,
responders and highly responders among different types of ESAs were observed in both
indications of use. Overall, around 15–20% of ESA users were non-responders. Strength of
treatment, but no type of dispensed ESAs was found to be predictor of responsiveness to
treatment.
Conclusions
No difference on the effects on hemoglobinemia among users of either biosimilars or refer-
ence product or ESAs covered by patent was observed in a general population from North-
ern Italy, despite a comparable dispensed dose of the different ESAs during the first three
months of treatment.
Introduction
Erythropoiesis-stimulating agents (ESAs) are biological analogues of human erythropoietin
that are produced by cell lines throughout recombinant DNA technology. The main indica-
tions for use of ESAs are the treatment of anemia associated to chronic kidney disease (CKD)
or chemotherapy-induced in cancer patients [1].
ESAs are indicated when hemoglobin (Hb) values are less than 11 g/dl in CKD patients and
10g/dl in the treatment of chemotherapy-induced anemia. In both indications, hemoglobine-
mia has to be maintained between 11 and 12g/dl [2], avoiding a rise in Hb greater than 2 g/dl
over a four week period.
To date, seven ESA medicinal products (i. e. epoetin alfa, beta, zeta, theta, darbepoetin alfa,
methoxypolyethyleneglycol-epoetin beta) are available on the Italian market.
Since 2007, epoetin alfa is one of a few biologics (in addition to filgrastim, somatropin, and,
more recently, follitropin alfa, infliximab, and glargine insulin) for which biosimilars are cur-
rently available in Europe, and other biosimilars will be introduced in the European market in
the near future (e.g. etanercept, pegfilgrastim, and trastuzumab). To date, US Food and Drug
Administration (FDA) approved a biosimilar of filgrastim for all indications included in the
reference product’s label.
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As relevant differences in the acquisition price between biosimilar and reference product
ranging from 15% to 30% have been documented [3–5], biosimilars represent an opportunity
for saving healthcare resources to be reallocated to innovative medicines [3].
Regulatory agencies define a biosimilar (follow-on biologic in US) as ‘‘a biological medicinal
product that contains a version of the active substance of an already authorized original biolog-
ical medicinal product (reference medicinal product)”. In Europe, biosimilars are centrally
approved by European Medicine Agency (EMA) based on “comprehensive comparability exer-
cise” which has to prove similarity of biosimilar to the reference product in terms of quality
characteristics, biological activity, safety and efficacy [6]. Nevertheless, biosimilars were not
immediately well perceived, especially in the first years after their marketing, as demonstrated
by the very low penetration of these drugs in most of the European Countries [7, 8].
Four pre-marketing clinical trials of biosimilar epoetin alfa were carried out on patients
with CKD-related anemia showing no differences between biosimilar and reference product in
achieving the Hb value target after 12 [9], 24 [10], 28 [11], or 56 [12] weeks of treatment. In
addition, Palmer SC et al. performed a recent meta-analysis of available randomized controlled
trials comparing the efficacy and safety of ESAs in patients with CKD, highlighting the lack of
sufficient evidence that might suggest the superiority of any ESA formulation [13]. Only one
double-blind, randomized, multicentre study was specifically carried out to assess the efficacy
and safety after 12 weeks of treatment with a biosimilar epoetin alfa in treating chemotherapy-
associated symptomatic anemia in patients with solid tumors [14]. On average, less than 500
patients were included in each premarketing randomized control study of biosimilar ESAs.
Taking into account evidence from post-marketing data, several observational studies
proved the effectiveness of epoetin zeta [15], darbepoetin alfa [16], or biosimilar epoetin alfa
[17] using real world data but without any comparator. Only one European multicenter retro-
spective study showed no difference about real-life clinical effectiveness and safety of biosimilar
epoetin alfa vs. darbepoetin alfa for 4–5 weeks considering 429 patients with chemotherapy-
induced anemia [18].
To further reassure about the comparability of effectiveness between biosimilar and origina-
tor ESAs, the aim of this observational, population-based study was to evaluate and compare
the effects of biosimilar, reference product and other ESAs still covered by patent on haemoglo-
binemia in chronic kidney disease (CKD) and cancer patients, separately, in a Local Health
Unit (LHU) from Northern Italy.
Material and Methods
Data Source
This was an observational, population-based, retrospective cohort study which is part of the
Italian Health Ministry funded project “Assessment of short and long term risk-benefit profile
of biologics through healthcare database network in Italy” (RF-2010.2320172) [8]. Fully anon-
ymized data were extracted from the administrative databases of Treviso LHU, covering a total
population of around 460,000 persons during the years 2009–2014. For each ESA prescription,
specialists have to fill an electronic therapeutic plan reporting exact drug name, number of dis-
pensed packages, dosing regimen and indication for use. This data can be linked through anon-
ymized patient unique identifier to other claims databases containing data on drug dispensing,
causes of hospitalization, healthcare service payment exemptions, outpatient diagnostic tests,
values of laboratory tests, etc.
Drug dispensing is coded by Anatomical Therapeutic Chemical (ATC) classification system
and the Italian marketing authorization code (AIC), which allows distinction between biosimi-
lar, reference product and other ESAs still covered by patent, while indication for use and
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causes of hospitalizations are coded by International Classification of Disease, 9th revision,
clinical modification (ICD9-CM). Additional details about data source can be found elsewhere
[8].
Study Population
Persons from the general population of Treviso LHU in the years 2009–2014 were included in
the study based on the following criteria:
1. at least one year of database history;
2. at least one ESA dispensing during the study period with no drug dispensing within the six
months prior (i.e. incident ESA users);
3. at least one hemoglobin measurement within one month prior to the date of the first ESA
dispensing (i.e. Index Date-ID), defined as baseline Hb value, and another measurement
between the 2nd and the 3rd month after ID (follow-up Hb value) (Fig 1). The same patient
could be included multiple times in the study in case of withdrawal of ESA treatment for at
least six months and the beginning of a new ESA treatment in the following period.
According to the Italian Medicines Agency, the term naïve patient refers to two specific cat-
egories: i) patients with no previous therapeutic exposure to originator (“primary naïve”); and
ii) patients with previous exposure to the originator but with a wash-out period of time ade-
quately long based on the judgment of the clinician (“secondary naïve”) [19]. So far there is no
consent about secondary naïve definition for epoetin users. Based on previous evidence sug-
gesting 5-fold half-life of epoetin as carry-over period, a 6 months wash out interval was con-
sidered as a reasonable time for identification of naïve users [20].
All analyses were stratified by indication for use and type of dispensed ESA at ID.
Study Drugs
The use of the following ESAs during the study period was assessed: epoetin alfa (ATC:
B03XA01; Eprex1, Abseamed1, Binocrit1), epoetin beta (B03XA01; Neorecormon1), dar-
bepoetin alfa (B03XA02; Aranesp1), epoetin zeta (B03XA01; Retacrit1), and methoxypo-
lyethyleneglycol-epoetin beta (B03XA03; Mircera1). Binocrit1, Abseamed1 and Retacrit1
are biosimilars of the reference product (Eprex1) (S1 Table), while all other ESAs are prod-
ucts still covered by the patent.
Fig 1. Depiction of follow-up period and Hbmeasurements. Hb = Hemoglobin.
doi:10.1371/journal.pone.0155805.g001
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For each ESA dispensing, information about marketing authorization code (AIC) and
brand name of the drug, dispensing date, number of dispensed packages of the drug were
retrieved from electronic therapeutic plan as well as pharmacy dispending records.
Data Analysis
Patients with ESA treatment (ESA users) were classified according to indication for use (CKD
and cancer) and type of dispensed ESA (biosimilar, reference product and other ESAs covered
by patent) at ID. Considering information collected in the electronic therapeutic plan, indica-
tion for use was mutually categorized as: (i) chronic kidney disease; (ii) cancer. In absence of
an available electronic therapeutic plan, the indications for use were derived from other claims
databases according to the algorithm described elsewhere [8].
At ID demographic and clinical characteristics (e.g. number of blood transfusions, hemoglo-
binemia and hematic level of creatinine, ferritin, folate, transferrin, vitamin B12, comorbidities
including diabetes mellitus, hypertension, end stage renal disease, heart failure, and concomitant
use of other iron preparations, folic acid, vitamin B12) of different ESA users has been evaluated.
The strength of ESA therapy (defined as total number of defined daily dose (DDD) dispensed
during the follow-up divided by days of follow-up) for biosimilar and other ESAs and the effect
on Hb values after three months from the start of ESA treatment were investigated. In particu-
lar, the difference between follow-up and baseline Hb values, i.e. delta Hb (ΔHb), was calculated
and ESA users were classified as non-responders (ΔHb0 g/dl), responders (0<ΔHb2 g/dl)
and highly responders (ΔHb>2 g/dl).
Sensitivity Analysis
In a sensitivity analysis the distribution of non-responders (ΔHb0 g/dl), responders
(0<ΔHb2 g/dl) and highly responders (ΔHb>2 g/dl) was evaluating incident ESA user only
at the first treatment episode.
Statistical Analysis
Descriptive statistics were used to describe all examined variables.
In particular, results were presented as mean ± standard deviation (SD) or median with
interquartile range depending on the underlying distribution for quantitative variables, and
were summarized by absolute frequencies and percentages for categorical variables. Continu-
ous and categorical variables were compared across groups according to type of ESA and indi-
cation for use at baseline using t-test or Chi-Square test (or Fisher's exact test when
appropriate) for continuous and categorical variables, respectively.
For the multiple comparisons (reference product vs. biosimilar; other ESA vs. biosimilar),
we applied Bonferroni’s correction, for which the significance alpha level 0.050 was divided by
the number of the possible pairwise comparisons than can be performed with three groups; so
the new “adjusted” significance level for this analysis is equal to 0.050 / 3 = 0.017.
In order to identify predictors of responsiveness of treatment with ESAs, univariate and
multivariate ordinal logistic regression models, as Cumulative Proportional Odds Models [21–
25] were performed stratifying by indication for use (CKD and cancer).
The dependent variable of the model was the responsiveness to ESA treatment, evaluated as
the difference between follow-up (within 2nd and 3rd month after ESA treatment start) and
baseline Hb values (ΔHb). It was expressed on three ordinal levels (non-responders: ΔHb0
g/dl; responders: 0>ΔHb2 g/dl; highly responders: ΔHb>2 g/dl).
As covariates we identified all the potential predictors of ESA responsiveness, including age,
sex, strength of ESA treatment, type of ESA at ID (biosimilar, reference product or ESA covered
Comparative Effectiveness of ESAs
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by patent), year of treatment, first ever use of ESAs, co-morbidities (heart failure, hypertension,
stage of CKD, dialysis), concomitant use of other drugs (e.g. folic acid, iron preparation, vitamin
A and/or D, vitamin B12) and laboratory values (sideremia).
In the multivariate model, we included all the covariates that are well known to be clinically
related to ESA responsiveness, irrespective of univariate analysis.
In order to evaluate if age, strength of ESA treatment, value of sideremia and baseline Hb
value individually act as effect modifiers of the association between ESAs exposure and respon-
siveness to treatment, on the basis of clinical relevance of the investigated covariates, their
interaction terms were individually included into the models and p-values were derived from
the test for fixed effects.
For each covariate tested as possible predictor of responsiveness to treatment with ESAs, the
ordered log-odds regression coefficients of the effect were reported along with 95% confidence
interval (95% CI).
All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC) and SPSS/
PC, Version 15 (SPSS Inc., Chicago, Illinois, USA). The significance level for all statistical tests
was set at p-value< 0.05.
Ethics Statement
This is an observational, retrospective, non-interventional study. In agreement with current
national law, the study protocol was notified to the Ethical Committee of Academic Hospital of
Treviso [26].
Written informed consent was not necessary as all data extracted from the database were
fully anonymized prior to the authors receiving the data set.
Results
During the study period, on a total population of 462,642 subjects registered in Treviso LHU,
1,727 (0.4%) received at least one incident ESA dispensing during the years 2009–2014; of
these, 1,003 (58.1%) ESA users had at least one baseline and one follow-up Hb measurement
[CKD = 583 (58.1%); cancer = 420 (41.9%)] (Fig 2).
As shown in Table 1, ESAs were in general more frequently used by males in CKD and
females in cancer, despite no statistically significant difference among various ESAs was
observed. Regarding age distribution, ESA users with CKD starting a treatment with a biosimi-
lar appear to be older (mean age ± SD: 80.4±8.7) than those starting with the reference product
(mean age ± SD: 64.5±14.7, p-value = 0.055) or ESAs covered by patent (mean age ± SD: 66.0
±16.1, p-value = 0.057), despite they did not reach statistical significance. CKD patients were
more likely to use a biosimilar ESA (89.3%) for the first time than a reference product (77.1%)
or an ESA covered by patent (78.3%). Blood transfusions before the starting treatment as well
as switch after ESA treatment start were rare, without any statistically significant difference
among ESA groups in both indications for use. On average, delta Hb after three months of
ESAs treatment was 1.6±1.8 g/dl in CKD and 1.7±1.7 g/dl in cancer, with no difference across
different types of ESAs.
CKD patients receiving the reference product or an ESA covered by patent were more likely
to be affected by end stage renal disease or hypertension and to use vitamin A/D than those
using a biosimilar (who were more likely to be affected by heart failure). In general, no statisti-
cally significant difference in baseline demographic characteristics of cancer patients using dif-
ferent ESAs was observed. No statistically significant differences in laboratory values within
three months prior to ID were found across users of different ESAs in both indications of use
(Table 2).
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The significance level of the results did not change after applying the Bonferroni’s correction.
As shown in Fig 3, there was no statistically significant difference in mean baseline Hb value
(g/dl) for biosimilars vs. reference product/other ESAs covered by patent in the two indications
for use, separately (CKD: biosimilars: mean±SD = 9.9±1.0 g/dL; reference product: mean
±SD = 10.4±1.2 g/dL; ESAs covered by patent: mean±SD = 10.2±1.1 g/dL; biosimilars vs refer-
ence product: p-value = 0.152; biosimilars vs ESAs covered by patent: p-value = 0.206; Cancer:
biosimilars: mean±SD = 9.6±0.9 g/dL; reference product: mean±SD = 9.9±1.2 g/dL; ESAs cov-
ered by patent: mean±SD = 9.6±1.1 g/dL; biosimilars vs reference product: p-value = 0.256;
biosimilars vs ESAs covered by patent: p-value = 1.000). The same held true for Hb value mea-
sured during the follow-up (CKD: biosimilars: mean±SD = 11.4±1.6 g/dL; reference product:
mean±SD = 12.3±1.7 g/dL; ESAs covered by patent: mean±SD = 11.8±1.5 g/dL; biosimilars vs
reference product: p-value = 0.124; biosimilars vs ESAs covered by patent: p-value = 0.224;
Cancer: biosimilars: mean±SD = 11.3±1.7 g/dL; reference product: mean±SD = 11.3±1.7
g/dL; ESAs covered by patent: mean±SD = 11.5±1.8 g/dL; biosimilars vs reference product:
p-value = 1.000; biosimilars vs ESAs covered by patent: p-value = 0.515).
As shown in Fig 4, no statistically significant difference in strength of ESA treatment among
different types of ESAs was found in either CKD (biosimilar: mean±SD = 1.5±1.1; reference
product: mean±SD = 1.6±1.1; ESAs covered by patent: mean±SD = 1.6±1.1) and cancer (biosi-
milar: mean ± SD = 4.3±2.3; reference product: mean±SD = 4.6±2.6; ESAs covered by patent:
mean ±SD = 3.8±2.0) patients, with much higher doses used to treat chemotherapy-induced
than CKD-related anemia.
Fig 2. Inclusion in the study of incident ESA users from Treviso LHU. Index Date (ID) = date of ESA treatment start;
LHU = Local Health Unit; ESA = Erythropoiesis-stimulating agents; Hb = Hemoglobin; CKD = Chronic Kidney Disease.
doi:10.1371/journal.pone.0155805.g002
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As observed in Fig 5, around 20% of ESA users were non-responders in both CKD and can-
cer. No differences across types of ESAs users were found in terms of distribution of responders
and highly responders in both indications for use.
In a sensitivity analysis we excluded ESAs users who were selected multiple times as study
patient and we did not find any difference in comparison to the main analysis.
As output of the univariate ordinal logistic regression model, the strength of treatment
(coefficient: 0.42; IC95%: 0.26/0.57; P-value<0.001) and the previous use of iron preparations
(coefficient: 0.45; IC95%: 0.05/0.86; P-value = 0.028) were statistically associated with an
Table 1. Demographic characteristics of incident ESA users, stratified by indication for use and type of ESA.
CKD Cancer
ESAs
covered
by patent
N = 189
(%)
Reference
product*
N = 131 (%)
Biosimilar
N = 263
(%)
P-value
vs ESAs
covered
by
patenta
P-value vs
Reference
producta
ESAs
covered
by patent
N = 114
(%)
Reference
product*
N = 121 (%)
Biosimilar
N = 185
(%)
P-value
vs ESAs
covered
by
patenta
P-value vs
Reference
producta
Sex
Male 112 (59.3) 81 (61.8) 152 (57.8) 0.755 0.442 52 (45.6) 59 (48.8) 86 (46.5) 0.883 0.696
Female 77 (40.7) 50 (38.2) 111 (42.2) 62 (54.4) 62 (51.2) 99 (53.5)
Age ± SD 66.0±16.1 64.5±14.7 80.4±8.7 0.057 0.055 68.1±12.2 64.3±13.7 68.7±11.8 0.748 0.211
Age groups
<65 81 (42.8) 60 (45.8) 12 (4.6) <0.001 <0.001 38 (33.3) 55 (45.5) 56 (30.3) 0.708 0.026
65–79 71 (37.6) 54 (41.2) 90 (34.2) 56 (49.1) 51 (42.1) 100 (54.0)
 80 37 (19.6) 17 (13.0) 161 (61.2) 20 (17.6) 15 (12.4) 29 (15.7)
First ever
use of
ESAsb
148 (78.3) 101 (77.1) 235 (89.3) 0.001 0.001 98 (85.9) 103 (85.1) 163 (88.1) 0.589 0.449
N. blood transfusionsc
0 168 (88.9) 111 (84.7) 220 (83.6) 0.223 0.560 108 (94.7) 107 (88.4) 165 (89.2) 0.248 0.964
1 17 (9.0) 19 (14.5) 37 (14.1) 6 (5.3) 11 (9.1) 15 (8.1)
2 3 (1.6) 1 (0.8) 6 (2.3) - 2 (1.7) 4 (2.2)
>2 1 (0.5) - - - 1 (0.8) 1 (0.5)
Switch
after IDd
6 (3.1) 4 (3.0) 5 (1.9) 0.386 0.470 2 (1.7) 3 (2.5) 3 (1.6) 0.931 0.597
Follow-upe
Mean±SD 70.3±16.1 70.4±16.2 68.6±16.4 0.470 0.489 74.0 ±16.4 75.5±14.3 73.9±15.7 0.966 0.526
Difference between the follow-up Hb value and the baseline Hb values (Delta Hb) (g/dl)
Mean±SD 1.6±1.8 1.8±1.8 1.4±1.7 0.444 0.281 1.9±1.8 1.4±1.7 1.6±1.7 0.388 0.498
Median
(q1-q3)
1.4 (0.4–
2.7)
1.7 (0.5–
3.1)
1.3 (0.2–
2.5)
1.8 (0.5–
3.0)
1.2 (0.5–
2.3)
1.6 (0.5–
2.5)
SD = Standard Deviation; CKD = Chronic kidney disease; ESAs = Erythropoiesis-stimulating agents; ID = Index Date (starting ESA treatment date);
Hb = Hemoglobin; q1-q3 = interquartile range;
*Reference product = Eprex;
a p-value from two-sample t-test or Chi-Square test (or Fisher's exact test when appropriate) for continuous and categorical variables, respectively;
b Number of ESA users without any ESA dispensing any time prior to ID;
c Number of blood transfusions within six months prior to baseline Hb value;
d Switch between starting ESA and another ESA was calculated within three months after ID;
e Number of days between Index Date and the date of follow-up Hb value;
doi:10.1371/journal.pone.0155805.t001
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Table 2. Distribution of comorbidities, concomitant drugs and labotratory values of incident ESA users, stratified by indication for use and type of
ESA.
CKD Cancer
ESAs
covered
by patent
N = 189
(%)
Reference
product*
N = 131 (%)
Biosimilar
N = 263 (%)
P-value
vs ESAs
covered
by patenta
P-value vs
Reference
producta
ESAs
covered
by patent
N = 114
(%)
Reference
product*
N = 121 (%)
Biosimilar
N = 185 (%)
P-value
vs ESAs
covered
by patenta
P-value vs
Reference
producta
Comorbiditiesb
Diabetes
mellitus
72 (38.0) 48 (36.6) 105 (39.9) 0.694 0.529 23 (20.2) 27 (22.3) 45 (24.3) 0.406 0.685
End Stage
Renal Disease
(on dialysis)
32 (16.9) 37 (28.2) 18 (6.8) 0.000 <0.001 - 2 (1.6) 1 (0.5) 0.432 0.334
Hypertension 181 (95.8) 117 (89.3) 228 (86.7) 0.001 0.458 72 (63.1) 70 (57.8) 116 (62.7) 0.937 0.395
Heart failure 35 (18.5) 28 (21.4) 95 (36.1) <0.001 0.003 5 (4.4) 7 (5.8) 8 (4.3) 0.979 0.563
Concomitant drugsc
Iron preparation 40 (21.2) 24 (18.3) 38 (14.4) 0.062 0.320 7 (6.1) 6 (4.9) 10 (5.4) 0.789 0.863
Vitamin A and/
or D
74 (39.1) 36 (27.5) 41(15.6) <0.001 0.005 7 (6.1) 14 (11.6) 20 (10.8) 0.171 0.836
Vitamin B12 - 1 (0.8) 9 (3.4) 0.010 0.114 2 (1.7) 3 (2.5) 2 (1.1) 0.622 0.345
Folic acid 20 (10.6) 11 (8.4) 32 (12.2) 0.602 0.258 10 (8.8) 16 (13.2) 12 (6.5) 0.462 0.046
Laboratory values: mean ±SD (n. ESAs users with 1 measurement within 3 months prior to ID)c
Albumin (g/dl;
normal range:
3.5–5.5)
3.7±0.6
(116)
3.7±0.5
(101)
3.5±0.5
(120)
0.166 0.166 3.8±0.5
(42)
3.8±0.7 (46) 3.7±0.6 (72) 0.364 0.419
Folate (ng/ml;
normal range:
2.7–17.0)
6.4±4.3
(30)
6.8±3.7 (23) 5.9±4.1 (92) 0.431 0.272 6.8±4.0
(21)
7.7±5.0 (18) 8.3±5.2 (24) 0.281 0.496
Ferritin (mcg/l;
normal range:
man: 60–300;
woman: 30–
150)
263.7
±269.9
(105)
326.6±324.7
(78)
283.7
±380.9
(150)
0.631 0.451 496.9
±576.2
(29)
510.1±573.7
(31)
439.6
±553.8 (43)
0.552 0.479
Transferrin (mg/
dl; normal
range: 200–
400)
221.9
±85.7 (17)
193.6±38.4
(10)
215.1±57.0
(34)
0.516 0.163 222.5
±47.4 (15)
205.8±36.9
(13)
245.9
±100.3 (9)
0.224 0.127
C-reactive
protein (mg/dl;
normal value:
<0.5)
2.3±3.3
(112)
2.3±4.4 (96) 2.7±3.6
(154)
0.436 0.533 2.2±3.2
(48)
3.6±6.6 (48) 3.3±4.2 (94) 0.237 0.733
Creatinine (mg/
dl; normal
range:man:0.7–
1.2; woman:
0.6–1.2)
3.5±2.3
(187)
2.9±1.9
(126)
2.7±1.5
(256)
0.149 0.483 0.9±0.4
(107)
1.1±0.9
(100)
1.0±0.5
(163)
0.307 0.465
Parathyroid
hormone (pg/ml;
normal
range:10–60)
272.6
±245.8
(87)
206.8±220.2
(51)
212.8
±191.6 (62)
0.219 0.834 33.0±25.6
(4)
47.5± 2.1 (2) 56.3±44.6
(9)
0.109 0.227
Potassium
(mEq/l; normal
range:3.6–5.0)
4.7±0.6
(183)
4.5±0.6
(124)
4.6±0.6
(250)
0.330 0.363 4.5±0.5
(82)
4.3±0.4 (80) 4.3±0.5
(137)
0.184 1.000
Vitamin B12 (ng/
ml; normal
range:300–900)
568.8
±228.2
(28)
489.2±247.4
(22)
452.9
±204.4 (97)
0.113 0.384 460.7
±195.3
(16)
557.1±245.7
(25)
465.9
±189.5 (20)
0.858 0.178
(Continued)
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increase of responsiveness, while first ever use of ESAs (coefficient: -0.43; IC95%: -0.83/-0.21;
P-value = 0.039) and a previous history of heart failure (coefficient: -0.39; IC95%: -0.73/-0.51;
P-value = 0.024) were associated with a decrease of responsiveness in CKD patients. A previous
use of vitamin B12 (coefficient: -1.45; IC95%: -2.87/-0.03; P-value = 0.046) seemed associated
Table 2. (Continued)
CKD Cancer
ESAs
covered
by patent
N = 189
(%)
Reference
product*
N = 131 (%)
Biosimilar
N = 263 (%)
P-value
vs ESAs
covered
by patenta
P-value vs
Reference
producta
ESAs
covered
by patent
N = 114
(%)
Reference
product*
N = 121 (%)
Biosimilar
N = 185 (%)
P-value
vs ESAs
covered
by patenta
P-value vs
Reference
producta
Sideremia
(mcg/dl; range:
man: 75–160;
normal woman:
60–150)
59.3±29.8
(104)
57.4±29.7
(86)
59.3±50.5
(141)
1.000 0.720 63.7±46.4
(59)
72.2±42.3
(49)
69.2±52.9
(65)
0.518 0.680
SD = Standard Deviation; CKD = Chronic kidney disease; ESAs = Erythropoiesis-stimulating agents; ID = Index Date (starting ESA treatment date);
q1-q3 = interquartile range;
*Reference product = Eprex;
a p-value from two-sample t-test or Chi-Square test (or Fisher's exact test when appropriate) for continuous and categorical variables, respectively;
b Co-morbidities have been evaluated any time prior to ID;
c Concomitant drugs and laboratory values have been evaluated within three months prior to ID.
doi:10.1371/journal.pone.0155805.t002
Fig 3. Effect of ESAs on Hbmeasurements within the follow-up Hb value from the start of the treatment, stratified
by indication for use.Hb = hemoglobin; CKD = Chronic kidney disease; ESAs = Erythropoiesis-stimulating agents.
doi:10.1371/journal.pone.0155805.g003
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with a decrease of responsiveness in cancer patients. Type of ESA was not associated to respon-
siveness in both indications of use.
After adjusting for all potential clinical confounders, previous history of heart failure, first
ever use of ESAs and previous use of iron preparation in CKD and previous use of vitamin B12
in cancer patients lost the statistical significance; type of ESA did not remain a predictor of
responsiveness to treatment for both indications for use. On the other hand, previous history
of hypertension and strength of ESA treatment were associated with an increase of responsive-
ness to ESA treatment in CKD, while sex (male) was negatively associated with responsiveness
to ESA treatment in cancer (Table 3).
The association between exposure to different ESAs and responsiveness to the treatment
was not significantly modified by the age, sideremia or baseline Hb value in CKD and cancer.
Only the strength of treatment is an effect modifier of the responsiveness in CKD ESAs users
(p-value<0.001).
Discussion
To our knowledge this is the first population based-study which compared the effects of biosi-
milar vs. reference product and vs. other ESAs covered by patent on haemoglobinemia in both
CKD and cancer patients using real world data.
Overall, our results suggested that the effect on Hb values after three months of treatment
was comparable among various types of ESAs both in CKD or cancer (patients.
These findings were in line with pre-marketing randomized clinical trials (RCTs), in which
Hb response was defined as an increase in Hb concentration of 2.0 g/dl from the mean value
from baseline to weeks 5–12 of the study [14] or end of week 13 after the treatment start [27],
Fig 4. Mean strength of ESA treatment during the whole follow-up, stratified by indication for use and type of ESA.
CKD = Chronic kidney disease; ESAs = Erythropoiesis-stimulating agents.
doi:10.1371/journal.pone.0155805.g004
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and post-marketing studies. Pre-marketing RCTs investigated mostly the comparative thera-
peutic efficacy and safety of reference product and biosimilar ESAs in the treatment of CKD-
related anemia, highlighting no differences in achieving the target Hb value [9–11]. The first
two clinical trials compared the efficacy and safety of epoetin zeta (biosimilar of epoetin alfa)
vs. epoetin alfa, administered intravenously [9, 10], achieving a similar target of Hb value
(epoetin zeta: 11.6±1.3 g/dL; epoetin alfa: 11.6±1.4 g/dL) over the last 4 weeks, on a total of 24
weeks of treatment [10]. A study on 462 anemic patients with end stage renal failure on chronic
hemodialysis demonstrated the therapeutic equivalence in maintaining the Hb concentration
of epoetin zeta and epoetin alfa administered subcutaneously [11]. So all these RCTs suggested
that epoetin zeta is a clinically equivalent, well-tolerated alternative to epoetin alfa in patients
with renal anemia.
To date, only one randomized, multicentre, double blind study was performed to evaluate
the efficacy and safety of a biosimilar of epoetin alfa in the treatment of chemotherapy-induced
anemia. Seventy-four patients were allocated to treatment with biosimilar of epoetin alfa and
40 patients were allocated to treatment with reference product ESAs. [14].
On average, a small sample of patients was eligible in each premarketing RCT of biosimilar
ESAs both in CKD (460 patients) and cancer (114 patients). On the contrary, in our study, we
Fig 5. Responsiveness to ESA treatment, assessed as delta Hb (ΔHb) between follow-up and baseline Hb value, stratified by indication
for use and type of ESA. Hb = hemoglobin; CKD = Chronic kidney disease; ESAs = Erythropoiesis-stimulating agents; Ref. Product = Reference
Product.
doi:10.1371/journal.pone.0155805.g005
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included more than 1,000 patients affected by CKD (N = 583) or cancer (N = 420) from a gen-
eral population from Northern Italy.
Our findings were also confirmed by a multicenter retrospective study evaluating the com-
parative effectiveness of biosimilar of epoetin alfa vs. darbepoetin alfa after about four weeks of
treatment in cancer patients from a community-based single German center (mean baseline
Hb value (g/dL): biosimilar: 9.8; darbepoetin alfa: 9.9; mean Hb at end of ESA treatment (g/
dL): biosimilar: 11.9; darbepoetin alfa: 11.9). Similar results were found in a large oncology
department of a Spanish hospital with biosimilar and darbepoetin alfa (mean baseline Hb
value (g/dL): 9.3; mean Hb at end of ESA treatment (g/dL): 10.8) [18].
More importantly, we did not find any statistically significant difference between biosimilars
and reference product/ESAs covered by patent in terms of responsiveness, despite a compara-
ble prescribed cumulative dose of drug during the observation period. This finding is in con-
trast with the results reported in a recently published research letter of Minutolo R. et al.
showing that switching from ESA originator to biosimilar may require higher doses of biosimi-
lar ESA to maintain Hb levels [28]. Several differences may explain the differences observed in
ours and Minutolo’s study: a) we investigated all naïve users of different ESAs while Minutolo
Table 3. Multivariate Ordinal Logistic Regression Model for responsiveness to first three months of ESA therapy.
CKD Cancer
Coefficient (95% CI) P-value Coefficient (95% CI) P-value
Variables
Sex (Males) -0.14 (-0.58/0.30) 0.525 -0.92 (-1.54/-0.31) 0.003
Age -0.05 (-0.02/0.01) 0.574 0.003 (-0.02/0.03) 0.827
Type of ESA
Biosimilar Comparator
Reference Product 0.25 (-0.37/0.87) 0.435 -0.07 (-0.85/0.71) 0.859
ESAs covered by patent -0.29 (-1.02/0.44) 0.436 -0.07 (-0.84/0.70) 0.867
First ever use of ESA treatment 0.35 (-0.29/0.99) 0.285 0.52 (-0.57/1.60) 0.351
Strength of ESA treatment 0.35 (0.15/0.56) <0.001 0.02 (-0.12/0.16) 0.815
Year of treatment -0.06 (-0.28/0.15) 0.571 -0.17 (-0.44/0.10) 0.209
Comorbidities
Heart failure -0.40 (-0.90/0.10) 0.120 -0.75 (-2.04/0.54) 0.253
Hypertension 1.04 (0.28/1.80) 0.007 0.24 (-0.45/0.93) 0.494
Dialysis -0.55 (-1.36/0.26) 0.181 - -
CKD stage
1–3 -0.10 (-0.81/0.61) 0.786 - -
4 -0.31 (-1.02/0.40) 0.391 - -
5 and dialysis Comparator
Concomitant drugs
Iron preparation 0.23 (-0.35/0.81) 0.436 0.21 (-0.79/1.21) 0.678
Vitamin B12 -0.33 (-1.77/1.11) 0.653 -1.86 (-3.91/0.18) 0.074
Vitamin A and/or D -0.11 (-0.64/0.42) 0.675 0.15 (-1.22/1.53) 0.828
Folic acid 0.09 (-0.61/0.80) 0.791 0.53 (-0.58/1.64) 0.348
Laboratory value
Sideremia 0.002 (-0.003/0.007) 0.466 0.002 (-0.004/0.008) 0.544
CKD = Chronic kidney disease; ESAs = Erythropoiesis-stimulating agents; CI = Confidence Interval.
doi:10.1371/journal.pone.0155805.t003
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et al. analysed only the switchers from originator to biosimilar. As renal functionality declines
progressively thus requiring generally higher doses of all ESAs over time to achieve target Hb,
it may be more appropriate to investigate all possible switch between biosimilars and reference
product/other ESAs covered by patent and vice versa; b) we conducted a population-based
study while Minutolo et al. conducted a multi-center study where patients with stable ESA
originator doses were previously selected, thus preventing the generalization of the results to
the whole spectrum of the hemodialysis population.
Importantly, we found that 15–20% of ESA users were not responders, with no significant
differences across various ESAs. So, efforts should be put to find factors associated with poor
response in ESA-resistant patients, irrespective of the ESA being prescribed.
Strengths and Limitations
The main strength of this population-based study is the possibility to explore Hb value changes
as a result of all available ESAs using real world data on a population level for more than 1,000
ESA users.
Most of the previous RCTs were conducted only considering CKD patients, while our study
compared the effectiveness of biosimilar and reference product/ ESAs covered by patent on
haemoglobinemia both in CKD and in cancer patients.
Availability of electronic therapeutic plans provides information on the exact brand name,
dosing regimen, and indication for use. Moreover, availability of laboratory values provides
clinically relevant information regarding some resistance-factors to ESA treatments (e.g. C-
reactive protein, high levels of parathyroid hormone, low levels of vitamin B12, and folate).
Some limitations warrant caution. Some ESA dispensing as well as concomitant drugs (i.e.
iron preparations) might not have been captured by the LHU database, as drugs can be initially
dispensed directly in the hospital. However, it is unlikely that this limitation affected the study
results as misclassification is expected to be minimal and non-differential across different types
of ESAs.
Conclusions
No difference on the short-term effects on hemoglobinemia among users of biosimilar ESAs or
reference product/ESAs covered by patent was observed in a general population from Northern
Italy, despite a comparable dispensed dose of different ESAs during the first three months of
treatment.
Supporting Information
S1 Table. Available ESAs in Treviso LHU database during the study years.
ATC = Anatomical Therapeutic Chemical (ATC) Classification System; CKD = Chronic kid-
ney disease. Note: some study drugs (Nespo: darbepoetin alfa; Abseamed, Globuren: epoetin
alfa; Eporatio: epoetin theta) were marketed in Italy, but they were not available in Treviso
database.
(PDF)
Acknowledgments
All authors would like to thank Domenico Meduri for his support in the statistical analyses.
Comparative Effectiveness of ESAs
PLOSONE | DOI:10.1371/journal.pone.0155805 May 17, 2016 14 / 16
Author Contributions
Conceived and designed the experiments: GT DS. Performed the experiments: GT YI FG. Ana-
lyzed the data: FG YI GT VI. Contributed reagents/materials/analysis tools: GT AC JB RP AA
AF. Wrote the paper: YI FG AF DS AA JB RP AC IM AG AC GT.
References
1. Aapro Matti S and Link Hartmut. September 2007 Update on EORTCGuidelines and Anemia Manage-
ment with Erythropoiesis-Stimulating Agents. The Oncologist. 2008; 13:33–6. doi: 10.1634/
theoncologist.13-S3-33 PMID: 18458123
2. Determinazione AIFA. Aggiornamento del Piano terapeutico AIFA per prescrizione SSN di Eritropoie-
tine (ex Nota 12). Available: http://www.agenziafarmaco.gov.it/sites/default/files/2010-07-29_
determina_aggiornamento_template_nota_12_g.u._75_del_31-03-2009.pdf.
3. Zuniga L, Calvo B. Biosimilars—the way forward. Hosp Pharm Europe. 2010; 50:33–4.
4. Mellstedt H. The future of biosimilars. Hosp Pharm Europe. 2010; 49: 33–34.
5. Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, et al. Biosimilar drugs: con-
cerns and opportunities. Biodrugs. 2007; 21:351–6. PMID: 18020619
6. EuropeanMedicines Agency. Committee for Medicinal Products 569 for Human Use (CHMP): guideline
on similar biological 570 medicinal products containing biotechnology-derived proteins as active sub-
stance: non-clinical and clinical issues. Available: http://www.ema.europa.eu/docs/en_GB/document_
library/Scientific_guideline/2013/06/WC500144124.pdf.
7. Loiacono C, Sgroi C, Coppolino S, Cannata A, Ferrara R, Arcoraci V, et al. Howmuch are biosimilars
used in southern Italy? a retrospective analysis of epoetin utilization in the local health unit of Messina
in the years 2010–2011. BioDrugs. 2012 Apr 1; 26(2):113–20. doi: 10.2165/11630770-000000000-
00000 PMID: 22385406
8. Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, et al. HowMuch Are Biosimilars
Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulat-
ing Agents in the Years 2009–2013. BioDrugs. 2015 Jul 14.
9. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Compari-
son of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia
treatment. Curr Med Res Opin. 2008; 24(3):625–37. doi: 10.1185/030079908X273264 PMID:
18208642
10. Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R, et al. Comparison of the
therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res
Opin. 2008; 24(5):1407–15. doi: 10.1185/030079908X297402 PMID: 18394266
11. Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, et al. Therapeutic
Equivalence of Epoetin Zeta and Alfa, Administered Subcutaneously, for Maintenance Treatment of
Renal Anemia. Adv Ther (2010) 27(2):105–117. doi: 10.1007/s12325-010-0012-y PMID: 20369312
12. Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety
of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin
Nephrol. 2009; 72(5):380–90. PMID: 19863881
13. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating
agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Data-
base Syst Rev. 2014; 12:CD010590. doi: 10.1002/14651858.CD010590.pub2 PMID: 25486075
14. Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the
treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie.
2009 Apr; 32(4):168–74. doi: 10.1159/000200783 Epub 2009 Mar 6. PMID: 19372711
15. Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, et al. BiOsimilaRs in the man-
agement of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the
ORHEO observational study. BMCCancer. 2014; 14:503. doi: 10.1186/1471-2407-14-503 PMID:
25011615
16. Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, et al. Evaluation of clinical use
and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Curr Med
Res Opin. 2012; 28(1):57–67. doi: 10.1185/03007995.2011.639352 PMID: 22070513
17. Kerkhofs L, Boschetti G, Lugini A, Stanculeanu DL, Palomo AG. Use of biosimilar epoetin to increase
hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Future
Oncol. 2012; 8(6):751–6. doi: 10.2217/fon.12.39 PMID: 22443466
Comparative Effectiveness of ESAs
PLOSONE | DOI:10.1371/journal.pone.0155805 May 17, 2016 15 / 16
18. Garzotto AR, Heine O, Turner M, Rebollo Laserna F, Lorenz A. Erythropoiesis-stimulating agents for
the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience. Jour-
nal of Blood Medicine. 2014; 5: 43–48. doi: 10.2147/JBM.S57887 PMID: 24855398
19. Agenzia Italiana del Farmaco. Position Paper sui farmaci biosimilari. Available: http://www.
agenziafarmaco.gov.it/it/content/position-paper. Accessed 2 Feb 2 2014.
20. Morkeberg J, Lundby C, Nissen-Lie G, Nielsen TK, Hemmersbach P, Damsgaard R. Detection of dar-
bepoetin alfa misuse in urine and blood: preliminary investigation. Med Sci Sports Exerc. 2007; 39:
1742–7. PMID: 17909401
21. Ananth CV, Kleinbaum DG. Regression models for ordinal responses: A review of methods and appli-
cations. International Journal of Epidemiology. 1997; 26, 1323–1333. PMID: 9447413
22. Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Bio-
metrics. 1990; 46, 1171–1178. PMID: 2085632
23. O’Connell A A. Logistic regression models for ordinal response variables. Thousand Oaks, CA:
SAGE. 2006.
24. Agresti A. 2010. Analysis of Ordinal Categorical Data, Wiley, 2nd ed.
25. Liu I, and Agresti A. 2005. The analysis of ordered categorical data: An overview and a survey of recent
developments (with discussion). Test 14: 1–73.
26. Ministero della Salute, Agenzia Italiana del Farmaco. Circolare AIFA del 3 agosto 2007. Linee guida
per la classificazione e conduzione degli studi osservazionali sui farmaci. Available: http://xoomer.
virgilio.it/pgiuff/osservazionali.pdf.
27. Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and effi-
cacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-
center, randomized, double-blind study. Clin Nephrol. 2012 Jan; 77(1):8–17. PMID: 22185963
28. Minutolo R, Borzumati M, Sposini S, Abaterusso C, Carraro G, Santoboni A, et al. Dosing Penalty of
Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable
Hemodialysis Patients. Am J Kidney Dis. 2016 Feb 13.
Comparative Effectiveness of ESAs
PLOSONE | DOI:10.1371/journal.pone.0155805 May 17, 2016 16 / 16
